Is Corvus Pharmaceuticals Stock a Good Investment?
Corvus Pharmaceuticals Investment Advice | CRVS |
- Examine Corvus Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Corvus Pharmaceuticals' leadership team and their track record. Good management can help Corvus Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Corvus Pharmaceuticals' business and its evolving consumer preferences.
- Compare Corvus Pharmaceuticals' performance and market position to its competitors. Analyze how Corvus Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Corvus Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Corvus Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Corvus Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Corvus Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Corvus Pharmaceuticals Stock
Researching Corvus Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 59.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.99. Corvus Pharmaceuticals had not issued any dividends in recent years.
To determine if Corvus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Corvus Pharmaceuticals' research are outlined below:
| Corvus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corvus Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (27.03 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Corvus Pharmaceuticals currently holds about 56.72 M in cash with (23.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Corvus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 11b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma |
Corvus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Corvus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Corvus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Corvus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Corvus Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-19 | 2023-12-31 | -0.12 | -0.14 | -0.02 | 16 | ||
2025-03-17 | 2024-12-31 | -0.12 | -0.1429 | -0.0229 | 19 | ||
2022-05-05 | 2022-03-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2021-08-02 | 2021-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2020-04-30 | 2020-03-31 | -0.4 | -0.44 | -0.04 | 10 | ||
2020-03-05 | 2019-12-31 | -0.33 | -0.38 | -0.05 | 15 | ||
2016-11-03 | 2016-09-30 | -0.45 | -0.51 | -0.06 | 13 | ||
2024-08-06 | 2024-06-30 | -0.11 | -0.04 | 0.07 | 63 |
Know Corvus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corvus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corvus Pharmaceuticals backward and forwards among themselves. Corvus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Corvus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 584.5 K | Geode Capital Management, Llc | 2024-12-31 | 566.9 K | Sphera Funds Management Ltd. | 2024-12-31 | 500.5 K | Ghost Tree Capital, Llc | 2024-09-30 | 500 K | Qube Research & Technologies | 2024-12-31 | 450.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 397.4 K | Renaissance Technologies Corp | 2024-12-31 | 390.7 K | State Street Corp | 2024-12-31 | 205.5 K | Millennium Management Llc | 2024-12-31 | 154.9 K | Orbimed Advisors, Llc | 2024-12-31 | 6.9 M | Samlyn Capital, Llc | 2024-12-31 | 6.7 M |
Corvus Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 273.09 M.Market Cap |
|
Corvus Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.90) | (0.95) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.90) | (0.95) | |
| Return On Equity | (1.91) | (1.82) |
Determining Corvus Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Corvus Pharmaceuticals is a good buy. For example, gross profit margin measures Corvus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Corvus Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Corvus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corvus Pharmaceuticals. Check Corvus Pharmaceuticals' Beneish M Score to see the likelihood of Corvus Pharmaceuticals' management manipulating its earnings.
Evaluate Corvus Pharmaceuticals' management efficiency
Corvus Pharmaceuticals has return on total asset (ROA) of (0.283) % which means that it has lost $0.283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0048) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.95 in 2025. Return On Capital Employed is likely to drop to -0.86 in 2025. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2025, whereas Other Assets are likely to drop 0.86 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.53 | 0.51 | |
| Tangible Book Value Per Share | 0.53 | 0.51 | |
| Enterprise Value Over EBITDA | (11.57) | (12.15) | |
| Price Book Value Ratio | 10.02 | 10.52 | |
| Enterprise Value Multiple | (11.57) | (12.15) | |
| Price Fair Value | 10.02 | 10.52 | |
| Enterprise Value | 318.7 M | 334.6 M |
The leadership approach at Corvus Pharmaceuticals' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.905 |
Basic technical analysis of Corvus Stock
As of the 26th of March, Corvus Pharmaceuticals shows the Standard Deviation of 6.12, risk adjusted performance of (0.06), and Mean Deviation of 3.98. Corvus Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Corvus Pharmaceuticals information ratio and kurtosis to decide if Corvus Pharmaceuticals is priced correctly, providing market reflects its regular price of 4.25 per share. Given that Corvus Pharmaceuticals has information ratio of (0.09), we suggest you to validate Corvus Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Corvus Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corvus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corvus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Corvus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corvus Pharmaceuticals' Outstanding Corporate Bonds
Corvus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Corvus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Corvus bonds can be classified according to their maturity, which is the date when Corvus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Corvus Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Corvus Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.4107 | |||
| Mean Deviation | 3.98 | |||
| Coefficient Of Variation | (1,189) | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.48 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | 0.4007 | |||
| Maximum Drawdown | 43.5 | |||
| Value At Risk | (5.76) | |||
| Potential Upside | 7.37 | |||
| Skewness | (3.00) | |||
| Kurtosis | 17.34 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.4107 | |||
| Mean Deviation | 3.98 | |||
| Coefficient Of Variation | (1,189) | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.48 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | 0.4007 | |||
| Maximum Drawdown | 43.5 | |||
| Value At Risk | (5.76) | |||
| Potential Upside | 7.37 | |||
| Skewness | (3.00) | |||
| Kurtosis | 17.34 |
Consider Corvus Pharmaceuticals' intraday indicators
Corvus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Corvus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Corvus Pharmaceuticals Corporate Filings
8K | 25th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 23rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 1st of August 2024 An amended filing to the original Schedule 13G | ViewVerify |
Corvus Stock media impact
Far too much social signal, news, headlines, and media speculation about Corvus Pharmaceuticals that are available to investors today. That information is available publicly through Corvus media outlets and privately through word of mouth or via Corvus internal channels. However, regardless of the origin, that massive amount of Corvus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Corvus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Corvus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Corvus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Corvus Pharmaceuticals alpha.
Corvus Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Corvus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Corvus Pharmaceuticals Maximum Pain Price Across June 20th 2025 Option Contracts
Corvus Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Corvus Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Corvus Pharmaceuticals' options.
Corvus Pharmaceuticals Corporate Management
| Leiv Lea | Chief Officer | Profile | |
| James MD | Senior Research | Profile | |
| Alan Esq | Sec | Profile | |
| MD FACP | CoFounder Director | Profile | |
| Jeffrey Arcara | Chief Officer | Profile |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.